Peter Gottlieb, MD

Peter Gottlieb, MD, is a Professor of Pediatrics and Medicine at the Barbara Davis Center (BDC) at the University of Colorado School of Medicine. Dr. Gottlieb is the holder of the Orr Family Endowed Chair in Adult Diabetes at the BDC. His areas of

research have included the immune mechanisms underlying T1D and other autoimmune diseases focusing on the role of antigen-specific T cells and B cells, which drive the immune process. Dr. Gottlieb has published more than 190 papers in the field. He has been a member of the NIDDK-sponsored Type 1 Diabetes TrialNet from its onset and is the chair of the Collaborative Mechanistic Studies Panel. Dr. Gottlieb has been a clinical investigator on many of the intervention trials performed through TrialNet, the Immune Tolerance Network (ITN), or industry, in both prediabetes (stage 1 and 2) and clinical diabetes (stage 3) over the last 20 years.

Dr. Gottlieb has been involved in translational research at the BDC, and along with Dr. Aaron Michels, spun out IM Therapeutics, Inc., from the BDC and the University of Colorado to develop small molecules to prevent the presentation of self-peptides in T1D and other autoimmune diseases. He received his MD from Rutgers Medical School and completed his residency in internal medicine and a fellowship in endocrinology at the University of Massachusetts Medical School. Dr. Gottlieb did his postdoctoral work in immunology at the Weizmann Institute in Rehovot, Israel.